<SEC-DOCUMENT>0001628280-23-026568.txt : 20230802
<SEC-HEADER>0001628280-23-026568.hdr.sgml : 20230802
<ACCEPTANCE-DATETIME>20230802070154
ACCESSION NUMBER:		0001628280-23-026568
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230802
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230802
DATE AS OF CHANGE:		20230802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		231133681

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ardx-20230802.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:7c254a24-8646-4c1f-b1fb-7a9186d83398,g:39c2e911-da47-4005-8e2e-8f244f15da7b,d:70a48f2851bf496ebb098084260c4846--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ardx-20230802</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001437402</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-24">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ardx-20230802.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i70a48f2851bf496ebb098084260c4846_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">August 2, 2023</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><img src="ardx-20230802_g1.jpg" alt="Image_0.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:75px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-4">ARDELYX, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-36485</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-7">26-1303944</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">400 FIFTH AVE.</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-9">SUITE 210</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">WALTHAM</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">MA</ix:nonNumeric>SSACHUSETTS&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including Zip Code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">510</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">745-1700</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-19">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-20">ARDX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-21">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i70a48f2851bf496ebb098084260c4846_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August&#160;2, 2023, Ardelyx, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended June&#160;30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished under this Item 2.02 shall not be considered &#8220;filed&#8221; under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under&#160;the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered &#8220;filed&#8221; or incorporated by reference therein.</span></div><div id="i70a48f2851bf496ebb098084260c4846_10"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:58.5pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ardx-20230630xexhibit991.htm">Press release of Ardelyx, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i70a48f2851bf496ebb098084260c4846_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 2, 2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARDELYX, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Justin Renz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Justin Renz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial and Operations Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ardx-20230630xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i11cca1cd3e3149ffa84bd456182a22b9_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:184px"></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Continued successful launch of IBSRELA, with Q2 net sales revenue of $18.3&#160;million&#59; Company currently expects 2023 full year IBSRELA net sales revenue to be $72 to $77 million</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">XPHOZAH expected to launch in Q4, pending FDA approval</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Company ends Q2 with $127.6&#160;million in cash and investments</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Conference call scheduled for 8&#58;00 AM Eastern Time</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">WALTHAM, Mass., August&#160;2, 2023 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">- Ardelyx, Inc. (Nasdaq&#58; ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the second quarter ended June&#160;30, 2023 and provided a business update. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8220;Ardelyx continued the momentum we established during a historic 2022 through the first half of 2023 and we are poised to deliver on our corporate priorities to drive IBSRELA growth and prepare for the potential approval and launch of XPHOZAH in the fourth quarter,&#8221; said Mike Raab, president and chief executive officer. &#8220;IBSRELA is carving out an important role in treating IBS-C, offering a meaningful new option for patients looking for a different approach to manage their IBS-C. With 61%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">quarter-over-quarter net sales revenue growth from Q1 to Q2 and usage and awareness continuing to increase, we are establishing IBSRELA as a meaningful therapeutic choice for patients and building market acceptance among the prescribing community, both of which are critical to our success. Now, with more than a year of launch metrics to work with, we are pleased, for the first time, to share that we expect IBSRELA net sales revenue to be between $72 and $77 million for the full year 2023. This guidance reflects continued, meaningful growth and we believe demonstrates the potential for this drug to generate $500 million or more of annual peak net sales revenue.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Raab continued, &#8220;We also have commercial launch preparations underway ahead of the goal review date for XPHOZAH of October 17. Pending FDA approval, we are looking forward to bringing this novel therapy to patients in the fourth quarter of this year, delivering on a promise to patients and the vision of Ardelyx for the second time in two years.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IBSRELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"> (tenapanor) Update&#58; Growth continues with $18.3&#160;million in net sales revenue in Q2 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Revenue for Ardelyx&#8217;s first commercialized product, IBSRELA, continued a persistent growth pattern, with the company reporting IBSRELA net sales revenue of $18.3&#160;million, a 61% quarter-over-quarter growth compared to $11.4&#160;million of net sales revenue reported in the first quarter of 2023. Launched in the U.S. in 2022 for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, IBSRELA has shown consistent growth across new and refill prescriptions as well as new and repeat writing healthcare providers. Spherix Global Insights, a premier market research firm that publishes independent, syndicated monthly tracking research, has included IBSRELA as one of the key gastrointestinal launches it tracks. The May 2023 LaunchDynamix report published in Q2 by Spherix reports significant increases in awareness and experience with IBSRELA, while continuing to rate the product highly, 12-months post-launch. Among the 76 gastroenterologists (GIs) surveyed in its market research in May 2023, 91% rate IBSRELA as either a substantial or moderate advance over currently available IBS-C therapies and among the surveyed GIs who reported using IBSRELA, 98% report high or moderate satisfaction.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">XPHOZAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:130%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%"> (tenapanor) Update&#58; New Drug Application (NDA) accepted&#59; User fee goal date of Oct. 17, 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">In May, Ardelyx announced that the U.S. Food and Drug Administration (FDA) had accepted the resubmitted New Drug Application (NDA) for XPHOZAH for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy. The FDA granted XPHOZAH a class 2, six-month review with a user fee goal date of October 17, 2023. The company is now preparing to launch XPHOZAH in the fourth quarter of 2023, pending FDA approval. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other Corporate Developments</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">In July, the company announced that an NDA for tenapanor had been accepted for review by China&#8217;s Center for Drug Evaluation of the National Medical Products Administration for the control of serum phosphorus in adult patients with chronic kidney disease on hemodialysis. This acceptance triggers a $2&#160;million milestone payment to Ardelyx under the terms of the license agreement between Ardelyx and its collaboration partner in China, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (Fosun Pharma). A potential approval of the NDA submission in China is expected by the end of 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:13.8pt">The company had a significant presence at the 2023 Digestive Disease Week Conference (DDW 2023) in Chicago, Ill from May 6-9. The company presented a poster which included a post-hoc data analysis from the Phase 3 T3MPO-2 study and sponsored a Product Theater titled&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Discover a Different Mechanism of Action to Treat Adults with IBS-C&#58; A Case Based Discussion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> where Darren Brenner, M.D., Professor of Medicine and Surgery, Northwestern University Feinberg School of Medicine, reviewed the multifactorial pathophysiology of IBS-C, the novel mechanism of action of IBSRELA, and efficacy and safety data of IBSRELA from the Phase 3 clinical trial program.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Second Quarter 2023 Financial Results</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cash Position&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> As of June&#160;30, 2023, the company had total cash, cash equivalents and short-term investments of $127.6&#160;million, as compared to total cash, cash equivalents and short-term investments of $123.9&#160;million as of December&#160;31, 2022. During the quarter ended June&#160;30, 2023, the company received gross proceeds of $11.6&#160;million for the sale of 3.0 million shares of the company&#8217;s common stock under the company&#8217;s sales agreement with Jefferies LLC deemed to be &#8220;at-the-market offerings.&#8221;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Revenues&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Net product sales for IBSRELA were $18.3&#160;million during the quarter ended June&#160;30, 2023, compared to $1.6&#160;million for the quarter ended June&#160;30, 2022. Total revenues for the second quarter were $22.3&#160;million, which included $4.0&#160;million of product supply and licensing related revenue compared to $1.0&#160;million in product supply and licensing related revenue in the same period in 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">R&#38;D Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#58; Research and development expenses were $8.3&#160;million for the quarter ended June&#160;30, 2023, compared to $9.7&#160;million for the quarter ended June&#160;30, 2022. R&#38;D expenses in the prior year included higher tenapanor manufacturing expenses as well as regulatory consulting expenses related to the appeal of the FDA&#8217;s July 2021 action on the NDA for XPHOZAH.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SG&#38;A Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Selling, general and administrative expenses were $27.2&#160;million for the quarter ended June&#160;30, 2023, an increase of $8.3&#160;million compared to $18.9&#160;million for the quarter ended June&#160;30, 2022. The increase in selling, general and administrative expenses was primarily due to increased costs associated with the ongoing commercial launch of IBSRELA.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Net Loss&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Net loss for the quarter ended June&#160;30, 2023 was $17.1&#160;million, or $(0.08) per share, compared to net loss of $26.9&#160;million, or $(0.19) per share, for the quarter ended June&#160;30, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Financial Guidance</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Ardelyx currently expects full-year 2023 net product revenue for IBSRELA to be between $72.0 and $77.0 million.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Conference Call Details</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The company will host a conference call today, August&#160;2, 2023, at 8&#58;00 AM ET to discuss these results. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. A webcast of the call can also be accessed by visiting the Investor page of the company's website, www.ardelyx.com, and will be available on the website for 30 days following the call.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">IMPORTANT SAFETY INFORMATION</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WARNING&#58; RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">IBSRELA is contraindicated in patients less than 6 years of age&#59; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONTRAINDICATIONS</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">WARNINGS AND PRECAUTIONS</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Risk of Serious Dehydration in Pediatric Patients</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old&#59; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years). </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Diarrhea </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">MOST COMMON ADVERSE REACTIONS </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The most common adverse reactions in IBSRELA-treated patients (incidence &#8805;2% and greater than placebo) were&#58; diarrhea (16% vs 4% placebo), abdominal distension (3% vs &#60;1%), flatulence (3% vs 1%) and dizziness (2% vs &#60;1%).</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">INDICATION </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Please see full Prescribing Information, including Boxed Warning, for additional risk information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:150%">About Ardelyx, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx&#8217;s first approved product, IBSRELA&#174; (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH&#174; (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis who have had an inadequate response or intolerance to phosphate binder therapy, which has completed three successful Phase 3 trials and an additional two Phase 4 open label trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and&#47;or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit https&#58;&#47;&#47;ardelyx.com&#47; and connect with us on Twitter, LinkedIn and Facebook.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Forward Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx&#8217;s expectation regarding opportunities for continued IBSRELA adoption, Ardelyx&#8217;s current expectation of the user fee goal date for the NDA for XPHOZAH and any subsequent commercial launch of XPHOZAH&#59; the projected net revenue for IBSRELA for full year 2023&#59; the timing of the review for the NDA for tenapanor for hyperphosphatemia in China&#59; and the potential role that tenapanor can play in offering a new treatment option for patients with hyperphosphatemia. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the development of, regulatory process for, and commercialization of drugs in the U.S. and internationally. Ardelyx undertakes no obligation to update or revise any forward-looking statements.  For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August&#160;2, 2023, and its future current and periodic reports to be filed with the Securities and Exchange Commission. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor and Media Contacts&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caitlin Lowie</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clowie&#64;ardelyx.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kimia Keshtbod </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">kkeshtbod&#64;ardelyx.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i11cca1cd3e3149ffa84bd456182a22b9_4"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx,&#160;Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:65.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,058</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,521</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,109</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,733</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid commercial manufacturing</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,166</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,567</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, current</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,617</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,295</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,064</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,053</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,320</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,203</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,066</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,294</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,859</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,880</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,548</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,105</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,894</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,052</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,197</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,236</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,571</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,380</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,752</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation related to the sale of future royalties</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,191</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,254</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,161</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,329</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,203</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,066</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Derived from the audited financial statements included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i11cca1cd3e3149ffa84bd456182a22b9_7"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx,&#160;Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:39.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,309&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,664&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,333&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,702&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of goods sold&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other cost of revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,997&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of goods sold</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,026&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,282&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,186&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,862&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,989&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,201&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,468&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,603&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,364&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,793&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,624)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,215)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,688)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,022)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,103)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,523)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense related to the sale of future royalties</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,937)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,121)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,932)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,880)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,001)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,121)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,938)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,894)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,009)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share of common stock - basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares used in computing net loss per share - basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,951,127&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,544,372&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,009,029&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,279,945&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ardx-20230802.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7c254a24-8646-4c1f-b1fb-7a9186d83398,g:39c2e911-da47-4005-8e2e-8f244f15da7b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ardx="http://www.ardelyx.com/20230802" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ardelyx.com/20230802">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20230802_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20230802_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ardelyx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ardx-20230802_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7c254a24-8646-4c1f-b1fb-7a9186d83398,g:39c2e911-da47-4005-8e2e-8f244f15da7b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_db92c109-71ed-4a22-98d6-e1f6c665b2e1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bb0d1b4f-3421-4db7-969e-ef39d43f3af0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_f6040616-0eb9-4151-8793-a50e70f51db5_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5e35de45-fab6-42d3-a65d-5467dcfa51ad_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_68468cc8-b93a-4cf7-bafd-b615ae400855_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f0d24ec7-f7c0-415e-88f2-87a844d40b39_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8ed3c423-1084-42c5-9505-766dd077f309_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b6b47c1b-87d9-46e3-bde3-d17ccfb21d66_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8ec0eddc-cf46-469e-bdef-3c70d892073b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_19902645-0a14-4065-8e7e-09403c94117d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_da884f43-91e6-469e-8c1c-bf6dac1c0122_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_300bf6c0-d8a7-4c06-9374-6d79b2e21c89_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_51fb791c-45f0-4f51-aea3-d9f3fe29b57c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_da357bd8-b1d4-43d7-86f2-6d3182fdbe69_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_981bd92e-8ada-4802-9d4a-86c6d46d3787_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f6f3dc75-99e8-47e6-8035-9927403dcc69_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e56fe70b-4c88-4c8b-8198-029aac17a436_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2dca4f29-aa73-4f2a-91d5-e32adb051e57_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2e1c09eb-0779-4010-a7a6-27419d856f2f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_edfa2e64-5696-4545-a76e-4fff97222ade_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2de6358e-aaa6-4064-b9c0-b41aa342d305_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_fabde239-2ec5-4843-a6f6-71354ceee48f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_af6b7f4e-cd44-4590-a548-7668b91a18f2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ardx-20230802_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7c254a24-8646-4c1f-b1fb-7a9186d83398,g:39c2e911-da47-4005-8e2e-8f244f15da7b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20230802.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7cdde177-76f2-433f-bccd-012ea3dbd883" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_DocumentType_7cdde177-76f2-433f-bccd-012ea3dbd883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_50e3b82c-0159-43d3-89b7-866fcf2ff369" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_DocumentPeriodEndDate_50e3b82c-0159-43d3-89b7-866fcf2ff369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7b61a608-47cf-4a36-9bc4-7bea6ceee8c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityRegistrantName_7b61a608-47cf-4a36-9bc4-7bea6ceee8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_48ecfc02-a293-421c-a541-ace38343e282" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityIncorporationStateCountryCode_48ecfc02-a293-421c-a541-ace38343e282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b782a7a5-0edc-4507-81a0-523b285563e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityFileNumber_b782a7a5-0edc-4507-81a0-523b285563e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_44580944-1c05-44d5-90f7-7df2e77fabfc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityTaxIdentificationNumber_44580944-1c05-44d5-90f7-7df2e77fabfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9b209ef8-fa58-4824-b7af-3189f2a40c67" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityAddressAddressLine1_9b209ef8-fa58-4824-b7af-3189f2a40c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_26ae5cb4-0c0e-4d0f-9472-2c4105a0cc4a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityAddressAddressLine2_26ae5cb4-0c0e-4d0f-9472-2c4105a0cc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e0b7ab1e-dfe1-4c05-9b33-a722d8c348a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityAddressCityOrTown_e0b7ab1e-dfe1-4c05-9b33-a722d8c348a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f1255ae6-0cad-437f-8b02-35a295049de9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityAddressStateOrProvince_f1255ae6-0cad-437f-8b02-35a295049de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_47ed47e8-5ca3-466e-b692-b93ec539d8a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityAddressPostalZipCode_47ed47e8-5ca3-466e-b692-b93ec539d8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_14781e4f-ab9c-4e1b-858c-9fa8ab959f79" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_CityAreaCode_14781e4f-ab9c-4e1b-858c-9fa8ab959f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ad13ad9e-a84f-4f7b-b2c6-29f01fe04678" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_LocalPhoneNumber_ad13ad9e-a84f-4f7b-b2c6-29f01fe04678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a9e2df92-1998-476f-8ea7-d559062831cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_WrittenCommunications_a9e2df92-1998-476f-8ea7-d559062831cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_545e5177-ef4a-46c2-906b-23d94e2aae83" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_SolicitingMaterial_545e5177-ef4a-46c2-906b-23d94e2aae83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_44957e76-6f97-47e9-9cfc-7ec3d8fbf951" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_PreCommencementTenderOffer_44957e76-6f97-47e9-9cfc-7ec3d8fbf951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_504ac5fe-65c8-47f0-8d42-fb3c68eafd7d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_504ac5fe-65c8-47f0-8d42-fb3c68eafd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e84ffa37-9651-46cc-8f07-d86fc69c4af5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_Security12bTitle_e84ffa37-9651-46cc-8f07-d86fc69c4af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f6a30dad-df8e-4afc-963f-e6a42661a9b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_TradingSymbol_f6a30dad-df8e-4afc-963f-e6a42661a9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_574562a4-021b-48df-98ee-4116978a0b31" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_SecurityExchangeName_574562a4-021b-48df-98ee-4116978a0b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bc161b1c-c088-438b-822c-a8384562b5ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityEmergingGrowthCompany_bc161b1c-c088-438b-822c-a8384562b5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_80f7b02d-4fca-468d-b9c7-f929b80dd266" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_EntityCentralIndexKey_80f7b02d-4fca-468d-b9c7-f929b80dd266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1dd974bb-c873-4cee-8a64-932193a5c67e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f1dcaa5-4196-4762-bfd7-6a99fbb3b457" xlink:to="loc_dei_AmendmentFlag_1dd974bb-c873-4cee-8a64-932193a5c67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ardx-20230802_g1.jpg
<TEXT>
begin 644 ardx-20230802_g1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K &L# 2(  A$! Q$!_\0
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%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBN0\1^
M(;FPNYK:"9"&5=H"\H>_/?/Z5C7KPH0<YFU"A.O-0@=)=:G96?\ K[A%]LYJ
MFOB?2';:MV,_[IKSRRMI]7U%(MQ9Y#RQYQ[UTEYX+6.S9[>?=,@R0>]>7#'X
MJLG.E!61ZD\!A:+4*LW=G90SQ3KNBD5Q['-25Y+8ZE=Z7/NAD9<'YD/0_45Z
M7I&J1ZK8K.G#='7T-=6"S".)]UJTCEQF EA_>3O$OT445Z!YX4444 %%%% !
M17G^LZS?P?%'1M.CN76UF!WQ@\-P:] H ***YKQY?7.G>$[NYM)6BF1?E93@
MCF@#I:*Q?"-U->^$=+N;B0R32P*SL>I-;5 !1110 4444 %%%% #)G\N"20?
MPJ3^0KR*\N&N[N6=B278MS7K=TI:TF4=3&P_2N \+Z?:W6HS6U[ LA4<!B>,
M5XV:4Y5:E.FGO<]G*ZD:5.I4:VL7O!=FJ+/J$G 4;5)Z8_R*=H6M&?Q%<I(Q
M,=P2%!/ _P XJL4U6VO6TN!'6U9B H'&TGUI?$-O:Z-?V;VD:Q.,,V">:YXR
ME2IQ<=%!Z^;9T2C&K4DI:N:T\DNYF>);$V6LR@#Y9#O'XU>\%WC1:FUN3\DB
MYQ[UJ>*K==0T6#48AD@ \>AK$\'PM+K:L.B*6-9.FZ..CR;-W7HS55%6P,N?
M=*S]4>BS!S"XB;;(5.T^A[5Y7=:9K+W4G]K>+(;:YW'9&CXS]1QBNR\>:C<Z
M9X2O;BT)67: &';)%<?X.\$:3K&A1ZC?W3W,\PR<O]P_XU],?,D_AOQ%KFD^
M*(M UB5+J*?'DS)SUQW[]:S=4U;Q/>?$'5-%TBXPK.$&[I&N <Y[56@T:WT+
MXJ:;:6MV]S'O4_.V2F<<5MZ#_P ECU[Z#^2T +?ZYJ7@?P]#ICW O-8N9CY9
M+;MH. .M06_A;QO=P_VA+JPBNW^98BV%_$=J9\1%.G^-=*U6YB+6>44L>@(/
M)_6O3X+ZUN+=)XIXS&ZA@=PZ&@#Q?3K[5KKXI:-%K486\MG,;,!C=\I.:Z;Q
M%XFUO5_$LOAWPYL3RN)ICV/.1TXK)O=3L]4^,>F&R(81.49QT8[360=-G?XB
MZG9MJ)TZ624E)#_&.?:@#H+S2/&GABU;4H-1^UI&-TL;'=QWP#VJYKOB*/Q+
M\+[J[ "S*NV5!_"V:AO?!E_!:2277BLBW"DN68=._:J$VAP:/\--6>TU%;V"
MX8.'4<=AZ#TH L:C/J6F_#+P_J>G3-&((D\X#H1VKT3P]JT>LZ#:WRN&+H-Y
M_P!K'/ZUC>%[6#5?AO863E'WV80C.=IP<5YK8^)9O"FBZUX?DWF<.8[<CJ,Y
MRW\J .MT74]1\4^-M0:*XD33+;**!P-PP,?SJO9>(M4\(>*WTW7YVEL)N(IV
M&,>AKIOA]H1T7PW&95Q<W/[V4^I/3]*Y3XFZG#K-[;^']/M1<WP;+2#^#V'O
MQ0!/J7B74?%?BJ/2?#\YCM(C^^G7OZUVFEV.LVFJS?:;M)=/V 1+CYMV!DD_
MG7 _#;4HM!U.X\/ZE;B"\9SME;^+GI7K5 !1110 5PVOV%WH^IG5+$D(QR2O
M8GKGVKN:;)&DJ%)%#*>H(R*YL5AU7A:]FMF=.&Q#H3O:Z>Z.!'C:_P!N/+BS
MCKMK"O[^XU&X,]PVYN@] *[:^\%VEPY>WD:$GG&,BJ*>!&+?/>8'LG_UZ\.O
MA,?/W)>\O4]NAB\##WH^Z_0Q[7Q!>KIQTY8TE1@5&5R>:Z[POHS:;9F688FE
MY(]!4^F>&['32'5/,E_O-S6Q7I8/!3@U.L[M;>1YV,QD)IPHJR>_F5[VS@U"
MSEM;F,/#(-K*:X+_ (5E/9S.NDZU/:6SGF/))KT6BO3/,.%TOX;6VF:Y:ZHM
MY+)+$=S[SG<:UK'PI'9>+;[71,6>[Q\G]WI_A7244 9VLZ)8Z]8-9W\6^(\C
MU!]17"?\*IDBD:*WUB6.R8X,7.<'J,UZ910!PVG?#33M)UW3]1LYG7[+DLKG
M)<\\_K6GXF\$:9XE99YE,5VHPLR<'V!KIJ* /-4^%3SN$U#6)I[8'[BD@XKL
M?^$7TL>'WT5(-MHR[2!U^M;-% ',>%/!\7A5[D0W+RQRXVJQ^[7"ZEI]IXF^
M+2Q6J%HH0K3M_"2O4?SKU^12\;*"5+ C([5@>'O"=IX?NKRYCD:6>Z?>[M^/
M^- &U-"QLV@@?RVV;5;TKG/#?@FVT&]FOY)6NKV4\ROSCZ5U5% '*^)O!-KX
MAO;>^64VUW"01*G4XZ5TEI%)!:QQ2R>8Z+@OZU-10 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140119294428208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARDELYX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1303944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 FIFTH AVE.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">WALTHAM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">745-1700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARDX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001437402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ardx-20230802_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ardx-20230802.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001437402</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-02</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-08-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-4">ARDELYX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-36485</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-7">26-1303944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">400 FIFTH AVE.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-9">SUITE 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">WALTHAM</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">745-1700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-19">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-20">ARDX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M"  Z. )7EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
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MUDX:?^:+X3]>?P%02P$"% ,4    "  Z. )7!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #HX E<M
M88CN[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( #HX E>97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ .C@"5[)."4-1!
M"!$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( #HX E>?H!OPL0(  .(,   -              "  90,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ .C@"5Y>*NQS     $P(   L
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64$L%!@     )  D /@(  .@3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ardx-20230802.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ardx-20230802.htm">ardx-20230802.htm</File>
    <File>ardx-20230630xexhibit991.htm</File>
    <File>ardx-20230802.xsd</File>
    <File>ardx-20230802_lab.xml</File>
    <File>ardx-20230802_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ardx-20230802_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ardx-20230802.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ardx-20230802.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ardx-20230802_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ardx-20230802_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ardx-20230802.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ardx",
   "nsuri": "http://www.ardelyx.com/20230802",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230802.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ardelyx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230802.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-23-026568-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-026568-xbrl.zip
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MF5E@>PEY!0PY@*%_GOW]V_\<_MU #O $<##XD0'[LV&QD0@\E/>?CP\9'XV
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MTF0@P&PR$L7$YG(AS#B4_3[8^\#@[YQI9PG^!<L:C>X1'Y-/ ]R;RMTDE2L
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M017F)W&P#ID/\[#7GN]4X14%(# SREU#=_Q*P*:(7B<#YRG6!0#IC)3>2ZC
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M0L$XNCO2%S/QK%_0T.K!8+R=<GM;Y7K1*GRMX_8$=IP]JZ$SUKMYC-BB7F.
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ML\G]\RG9*WQQ0Y+9 #J=DDK8!N.1"*_!?1]*KOMN*2")H>FFY(HPYO,Q4(T
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M[]E6K;V"KBA3>IM&4+O=+M%37/0XEEVKEP@J+H)LJ^F\#()VR<\^54'%Y=&
MR1E]RNB5SL)CL:+736/# KP,<I7$20C?JC'W8[EF%'][,T=[W=;JMOR66NS;
MB!Z[5F*GP-BQNO45K*(203O"/KODN.JN!3)PU5 L?"?<*S?LP*YKO& O^M+Z
M7BJ]6;X8I> 8<JQ.8\V:D1))&\LE-U^P6=,NW$&D-'%/7"EP24>ANI&15 &#
M/XV"93'_\3@?]76E+>RV93MVP=(693+J\8GC;KUHR:@2JX]-'->M3F=U?ZS$
M:J&QVFQ:M5K1)/ 3^=^%-A7.GM8\V%ZC].>W'<=V#DK?H=AH*F,D!4?0RF^
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M+WS\T,-=&'JDCZ=^]I0WAG\&\=#_^']02P,$%     @ .C@"5U8S0?O:#@
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M]R0&O.90'D\IR,Y E(!P^G=*?Z.7E=8>@,O$/8T?:";I(&!YA4$D  K=BX*
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M;2 /D#\0*:EH6QW/VX=UD#8(7>V&W0K&R[7[?K: 5K#;ZN7D"5!+ P04
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M$LA]:BM%B_[&)M E9&\#\R]>A=K0[*V0>R5T>_7:\+Y?TP=F\\A*/P213F'
M@9Y.P<'&_F AP\'9>B!QN:UK>'DGI1E'B\KNY_P\S[XGQIUIK*0O"/8!@C$Q
M2;<(  U@ *(PE!)&D?:A8UQI[FBD 64%MJ: -6#7,-+"KVW\Z,_:,(&C V$=
MPL5N-GK$B1;# P>(W>YM1X8][=U#PGFNRCI>&2OEV8R/B\6MRB_+;:W\L]:F
MI.0A)Y% W.07D@(2*A]P:?Y(% FA.48R#&W#PK[.QA8:#%X@:H"])6)O"=FK
M,-M'A[U4[X\0AR3PR%&B%W=.@<*6E$[!8J_QP0*&K9OUH&%]CWO@6)_F>CS
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M'+[Y+U!+ 0(4 Q0    ( #HX E=!%6X:N2,   Z) 0 <              "
M 0    !A<F1X+3(P,C,P-C,P>&5X:&EB:70Y.3$N:'1M4$L! A0#%     @
M.C@"5U8S0?O:#@  1F4  !$              ( !\R,  &%R9'@M,C R,S X
M,#(N:'1M4$L! A0#%     @ .C@"5^J/)SYJ @  ;0<  !$
M ( !_#(  &%R9'@M,C R,S X,#(N>'-D4$L! A0#%     @ .C@"5Y2F*=^'
M"0  "@H  !0              ( !E34  &%R9'@M,C R,S X,#)?9S$N:G!G
M4$L! A0#%     @ .C@"5[,#ZC.'"@  $V$  !4              ( !3C\
M &%R9'@M,C R,S X,#)?;&%B+GAM;%!+ 0(4 Q0    ( #HX E=+UH;%T@8
M /8R   5              "  0A*  !A<F1X+3(P,C,P.# R7W!R92YX;6Q0
52P4&      8 !@"0 0  #5$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
